Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:administered_by |
booster shot
|
| gptkbp:approves |
gptkb:2005
|
| gptkbp:associated_with |
herd immunity
|
| gptkbp:available_in |
liquid form
pre-filled syringe |
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:booster_frequency |
every 10 years
|
| gptkbp:clinical_trial |
ongoing
|
| gptkbp:community_health |
reduces incidence of diseases
|
| gptkbp:contains |
inactivated toxins
|
| gptkbp:contraindication |
severe allergic reaction
|
| gptkbp:developed_by |
gptkb:Centers_for_Disease_Control_and_Prevention
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tdap
|
| gptkbp:is_informed_by |
gptkb:literature
gptkb:guidelines community outreach programs patient education materials epidemiological data international health regulations healthcare provider education global health partnerships vaccine research funding vaccine advocacy groups vaccine safety studies vaccine access initiatives healthcare policy analysis public health recommendations vaccine distribution networks immunization registries adverse event reporting systems government health campaigns vaccine efficacy research vaccine financing models |
| gptkbp:is_recommended_by |
gptkb:World_Health_Organization
gptkb:American_Academy_of_Pediatrics |
| gptkbp:is_recommended_for |
adults
adolescents |
| gptkbp:is_vulnerable_to |
combination vaccine
high in developed countries low in some developing countries |
| gptkbp:marketed_as |
gptkb:Boostrix
Adacel |
| gptkbp:part_of |
immunization schedule
|
| gptkbp:requires |
informed consent
|
| gptkbp:route_of_administration |
intramuscular injection
|
| gptkbp:side_effect |
fatigue
headache fever pain at injection site |
| gptkbp:suitable_for |
pregnant women in first trimester
individuals with moderate to severe illness |
| gptkbp:targets |
gptkb:diphtheria
tetanus pertussis |
| gptkbp:bfsParent |
gptkb:GSK
|
| gptkbp:bfsLayer |
4
|